Adverum Biotechnologies, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Adverum Biotechnologies, Inc. has issued a supplement to its proxy statement, introducing more restrictive parameters for its proposed stock option repricing, including a longer service period and higher exercise price thresholds, aiming to garner stockholder approval at the upcoming Annual Meeting on June 17, 2025.
Adverum Biotechnologies, Inc. has filed a definitive proxy statement with the SEC.
Adverum Biotechnologies is holding its 2025 Annual Meeting of Stockholders on June 17, 2025, to vote on director elections, auditor ratification, executive compensation, and equity incentive plan amendments.
Adverum Biotechnologies announces the appointment of Rabia Gurses Ozden, M.D. as Chief Medical Officer and Szilrd Kiss, M.D. as a new director, effective June 10, 2024.
Adverum Biotechnologies updates its non-employee director compensation policy, adjusting cash and equity compensation based on the company's market capitalization.
Adverum Biotechnologies has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
DEF 14A: Adverum Biotechnologies Announces Upcoming Annual Stockholders Meeting and Equity Incentive Plan
Adverum Biotechnologies is set to hold its 2024 Annual Meeting of Stockholders on June 17, 2024, featuring proposals including director elections, auditor ratification, executive compensation, and a new equity incentive plan.